Pachymeningitis in Biopsy-Proven Sarcoidosis Clinical Course, Radiographic Findings, Response to Treatment, and Long-term Outcomes

被引:10
作者
Chakales, Pressley A. [1 ]
Herman, Max C. [1 ]
Chien, Ling Chen [2 ]
Hutto, Spencer K. [1 ]
机构
[1] Emory Univ, Sch Med, Dept Radiol, Dept Neurol, Atlanta, GA 30322 USA
[2] Emory Univ, Sch Med, Dept Radiol, Div Neuroradiol, Atlanta, GA 30322 USA
来源
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION | 2022年 / 9卷 / 06期
关键词
NEUROSARCOIDOSIS; SYSTEM; MANIFESTATIONS; EPIDEMIOLOGY;
D O I
10.1212/NXI.0000000000200028
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Objectives Meningeal inflammation is one of the most common manifestations of neurosarcoidosis, occurring in 16%-69% of affected patients. While the clinical and radiographic features of leptomeningitis in neurosarcoidosis are well known, those of pachymeningitis are far less clear. Our primary aim was to study the clinicoradiographic features of pachymeningeal involvement in neurosarcoidosis and its evolution over time in response to treatment. Methods Patients with a diagnosis of neurosarcoidosis seen at Emory University (January 2011-August 2021) were included if pachymeningeal involvement was evident by MRI and the patient's sarcoidosis was pathologically confirmed (from a CNS or non-CNS site). Results Twenty-six of 215 (12.1%) patients with neurosarcoidosis qualified for inclusion. Pathologic confirmation came from CNS tissue in 50%. The median age of onset was 43.5 years; most were male (16/26, 61.5%). Symptoms were primarily related to pachymeningitis in 20/26 (76.9%). Headache (19/26, 73.1%), visual dysfunction (12/26, 46.2%), and seizures (7/26, 26.9%) were the most common symptoms. All patients had cranial pachymeningitis; only a single patient undergoing spinal imaging (1/11, 9.1%) had spinal pachymeningitis. The falx cerebri (16/26, 61.5%) was the most commonly affected dural structure, but the anterior and middle cranial fossae and tentorium cerebelli were frequently involved (12/26 each, 46.2%). The pachymeningeal lesions were unifocal (11/26, 42.3%) or multifocal (15/26, 57.7%) in distribution, nodular morphologically (23/25, 92.0%), and homogeneously enhancing (24/25, 96.0%). Symptomatic improvement occurred with steroids initially in 22/25 (88.0%). Ultimately, 23/26 (88.5%) required initiation of steroid-sparing immunosuppressants, including 8/26 (30.8%) eventually undergoing TNF inhibition. Pachymeningeal relapses occurred in 7/26 (26.9%). The median clinical follow-up was 48 months. The median modified Rankin scale score at last follow-up improved to 1.0 from 2.0 at presentation. Discussion Pachymeningitis due to sarcoidosis often presents with headaches, visual dysfunction, and seizures; it usually affects the dura of the falx cerebri, anterior and middle cranial fossae, and tentorium cerebelli and tends to require steroid-sparing immunosuppressants. It has the potential to relapse, but the prospect for recovery is good.
引用
收藏
页数:10
相关论文
共 37 条
[1]   IgG4-related disease of the central and peripheral nervous systems [J].
AbdelRazek, Mahmoud A. ;
Venna, Nagagopal ;
Stone, John H. .
LANCET NEUROLOGY, 2018, 17 (02) :183-192
[2]   A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules [J].
Aspelund, Aleksanteri ;
Antila, Salli ;
Proulx, Steven T. ;
Karlsen, Tine Veronica ;
Karaman, Sinem ;
Detmar, Michael ;
Wiig, Helge ;
Alitalo, Kari .
JOURNAL OF EXPERIMENTAL MEDICINE, 2015, 212 (07) :991-999
[3]   Sarcoidosis in America Analysis Based on Health Care Use [J].
Baughman, Robert P. ;
Field, Shelli ;
Costabel, Ulrich ;
Crystal, Ronald G. ;
Culver, Daniel A. ;
Drent, Marjolein ;
Judson, Marc A. ;
Wolff, Gerhard .
ANNALS OF THE AMERICAN THORACIC SOCIETY, 2016, 13 (08) :1244-1252
[4]   Neurosarcoidosis of the Cauda Equina Clinical Course, Radiographic and Electrodiagnostic Findings, Response to Treatment, and Outcomes [J].
Bou, Gabriela Alejandra ;
Garcia-Santibanez, Rocio ;
Castilho, Alexander Jordan ;
Hutto, Spencer Kristian .
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2022, 9 (04)
[5]   Neurosarcoidosis Pathophysiology, Diagnosis, and Treatment [J].
Bradshaw, Michael J. ;
Pawate, Siddharama ;
Koth, Laura L. ;
Cho, Tracey A. ;
Gelfand, Jeffrey M. .
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (06)
[6]  
Carlson ML, 2015, OTOL NEUROTOL, V36, P156, DOI 10.1097/MAO.0000000000000501
[7]   Central nervous system involvement of granulomatosis with polyangiitis: clinical-radiological presentation distinguishes different outcomes [J].
De Luna, Gonzalo ;
Terrier, Benjamin ;
Kaminsky, Pierre ;
Le Quellec, Alain ;
Maurier, Francois ;
Solans, Roser ;
Godmer, Pascal ;
Costedoat-Chalumeau, Nathalie ;
Seror, Raphaele ;
Charles, Pierre ;
Cohen, Pascal ;
Puechal, Xavier ;
Mouthon, Luc ;
Guillevin, Loic .
RHEUMATOLOGY, 2015, 54 (03) :424-432
[8]   Infliximab treatment in pathology-confirmed neurosarcoidosis [J].
Fritz, Daan ;
Timmermans, Wilhelmina M. C. ;
van Laar, Jan A. M. ;
van Hagen, P. Martin ;
Siepman, Theodora A. M. ;
van de Beek, Diederik ;
Brouwer, Matthijs C. .
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2020, 7 (05)
[9]   Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis [J].
Fritz, Daan ;
van de Beek, Diederik ;
Brouwer, Matthijs C. .
BMC NEUROLOGY, 2016, 16
[10]   Infliximab for the treatment of CNS sarcoidosis A multi-institutional series [J].
Gelfand, Jeffrey M. ;
Bradshaw, Michael J. ;
Stern, Barney J. ;
Clifford, David B. ;
Wang, Yunxia ;
Cho, Tracey A. ;
Koth, Laura L. ;
Hauser, Stephen L. ;
Dierkhising, Jason ;
NgocHanh Vu ;
Sriram, Subramaniam ;
Moses, Harold ;
Bagnato, Francesca ;
Kaufmann, Jeffrey A. ;
Ammah, Deidre J. ;
Yohannes, Tsion H. ;
Hamblin, Mark J. ;
Venna, Nagagopal ;
Green, Ari J. ;
Pawate, Siddharama .
NEUROLOGY, 2017, 89 (20) :2092-2100